Critical Outcome Technologies Inc. home page
COTI Home page COTI Products Partnering with COTI COTI Discovery Process Investor Relations at COTI About COTI Contact COTI

 

HIV Integrase Inhibitors

The Need

The Human Immunodeficiency Virus (HIV) is the virus that causes Acquired Immunodeficiency Syndrome (AIDS). HIV attacks the immune system, resulting in a chronic, progressive illness and leaving infected people vulnerable to opportunistic infections and cancers. The median time from infection to AIDS diagnosis now exceeds 10 years. AIDS is often fatal. There is no cure.

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) there were 39.5 million people worldwide living with HIV. Moreover, in 2006 there were 4.3 million people newly affected with HIV. Also in 2006 there were 2.9 million deaths related to AIDS.

Our Solution

COTI believes that future optimal therapy will include a combination of a Reverse Transcriptase Inhibitor (RTI), a Protease Inhibitor (PI) and an Integrase Inhibitor (IntInh). HIV Integrase is the viral enzyme system responsible for incorporating viral DNA into host DNA resulting in chronic infection. Integrase inhibitors may also become an effective preventative therapy following accidental exposure.

A library of 10 low toxicity anti-HIV small molecules (EC50 < 1 µmol/l) which are also highly effective in silico against HIV Integrase (i.e. IC50 < 1 µmol/l) has been discovered and undergone final optimization.

 

Development Status

 

1

  Select a therapeutic target

2

  Identify novel validated cellular target(s)

3

  Design a candidate molecule library

4

  Profile/Optimize the candidates using in silico + traditional medicinal chemistry methods

5

  Conduct a patent search on most promising candidates

6

 
Synthesize the most
promising candidates
a. The HIV Integrase inhibitor library of lead compounds is ready to be synthesized.

7

  Test and develop in vitro / in vivo to confirm the computational predictions

8

  Patent the most promising candidates

9

  License successful candidates
   
 
© 2008 Critical Outcome Technologies Inc. All rights reserved.
 
Site designed by MFX Partners